Mesoblast Limited (MESO)

業務介紹

生物製藥公司Mesoblast Limited在美國、澳洲、新加坡、英國和瑞士開發和商業化異體細胞療法。該公司提供心血管、脊柱骨科疾病、腫瘤學、血液學以及免疫介導和炎症性疾病領域的產品。其專有的再生醫學技術平台基於稱為間充質系細胞的特殊細胞。該公司正在III期臨床試驗的產品包括:用於治療類固醇難治性急性移植物抗宿主病以及因COVID-19感染引起的急性呼吸窘迫綜合症的remestemcel-L;用於治療晚期慢性心力衰竭的Rexlemestrocel-L;以及用於治療由退行性椎間盤疾病引起的慢性腰痛的MPC-06-ID。該公司還在開發用於治療生物製劑難治性類風濕性關節炎和糖尿病腎病的MPC-300-IV。該公司與多家公司有戰略合作關係,包括在中國提供用於心力衰竭的MPC-150-IM和用於心臟病發作的MPC-25-IC的Tasly Pharmaceutical Group,用於治療鱗狀細胞皮膚病患者創傷癒合的JCR Pharmaceuticals Co. Ltd.,以及用於開發和商業化治療慢性腰痛的細胞療法的Grünenthal。Mesoblast Limited於2004年註冊成立,總部位於澳大利亞墨爾本。



Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

公司網址

https://www.mesoblast.com